Brilinta (ticagrelor) is a prescription blood-thinning medication that prevents blood clots by stopping platelets from clumping together. It is FDA-approved for three main purposes: reducing the risk of heart attack, stroke, and cardiovascular death in people with acute coronary syndrome or a history of heart attack; preventing a first heart attack or stroke in people with coronary artery disease who are at high risk; and reducing the risk of stroke after a minor ischemic stroke or transient ischemic attack (TIA).
How Brilinta Works
When you’re injured, platelets rush to the site and stick together to form a clot. This process relies on a chemical signal called ADP binding to a receptor on platelets called P2Y12. Brilinta blocks that receptor, which prevents the final step of platelet clumping. Unlike older blood thinners in the same class, Brilinta doesn’t just block the signal from ADP. It also dials down the receptor’s baseline activity, essentially quieting the clotting machinery even when no trigger is present.
Brilinta also has a secondary effect: it slightly increases levels of adenosine, a natural molecule in the body that further discourages platelet clumping. This dual action, blocking the receptor and boosting adenosine, is part of what distinguishes it from alternatives like clopidogrel (Plavix).
Acute Coronary Syndrome and Heart Attack
The most common reason people are prescribed Brilinta is after an acute coronary syndrome event, which includes heart attacks and episodes of severe chest pain caused by reduced blood flow to the heart. In this setting, Brilinta is taken alongside low-dose aspirin to prevent new clots from forming in narrowed or stented coronary arteries.
The landmark PLATO trial compared Brilinta to clopidogrel in over 18,000 patients with acute coronary syndrome. Globally, Brilinta reduced the combined risk of cardiovascular death, heart attack, and stroke by about 19% compared to clopidogrel, without a significant increase in major bleeding. Brilinta is also specifically effective at preventing stent thrombosis, a dangerous complication where a clot forms inside a newly placed coronary stent.
The standard approach after an acute coronary syndrome event is 12 months of dual antiplatelet therapy, meaning Brilinta plus aspirin. Current guidelines also endorse transitioning to Brilinta alone (without aspirin) after at least one month of combined therapy as a strategy to reduce bleeding risk while maintaining protection.
Preventing a First Heart Attack or Stroke
Brilinta is also approved for people with coronary artery disease who have never had a heart attack or stroke but are at high risk for one. This indication was studied primarily in patients with type 2 diabetes, a group with significantly elevated cardiovascular risk. In this setting, Brilinta is taken at a lower dose to provide ongoing protection against clot-related events.
Stroke Prevention After a TIA or Minor Stroke
The newest approved use for Brilinta is reducing stroke risk in people who have just experienced a minor ischemic stroke or a TIA (sometimes called a “mini-stroke”). In clinical trials, adding Brilinta to aspirin reduced the risk of a disabling stroke or death by 17% and cut the risk of a recurrent ischemic stroke by 22% compared to aspirin alone. Treatment in this setting is short, typically lasting up to 30 days.
Dosing Differences by Condition
Brilinta dosing varies depending on why you’re taking it. For all three uses, treatment starts with an initial loading dose of 180 mg. After that, the maintenance schedule differs:
- Acute coronary syndrome: 90 mg twice daily for the first year, then 60 mg twice daily if continued beyond 12 months.
- Coronary artery disease without prior heart attack or stroke: 60 mg twice daily.
- After a minor stroke or TIA: 90 mg twice daily for up to 30 days.
The twice-daily schedule is important. Unlike clopidogrel, which is taken once a day, Brilinta’s effects wear off faster. Missing doses or taking it only once daily can leave you unprotected.
The Aspirin Dose Restriction
If you take Brilinta with aspirin, the aspirin dose must stay low, generally no more than 100 mg daily. Higher doses of aspirin can actually reduce Brilinta’s effectiveness. This was a significant enough concern that the FDA placed a boxed warning on the label. If you’re prescribed Brilinta, over-the-counter pain relievers containing aspirin at standard doses (325 mg or more) should be avoided unless specifically directed otherwise.
Side Effects
The most notable side effect of Brilinta is shortness of breath. In clinical studies, nearly 39% of patients taking Brilinta reported some degree of shortness of breath, compared to about 9% on clopidogrel or placebo. This is typically mild to moderate and tends to occur within the first week of treatment. It often resolves on its own and does not appear to reflect any actual change in heart or lung function.
Bleeding is the other major concern, as it is with any antiplatelet drug. Minor bleeding events like bruising, nosebleeds, or bleeding gums are common. Serious bleeding is less frequent but possible, particularly if Brilinta is combined with other blood-thinning medications or taken before surgery. Current guidelines recommend stopping Brilinta 5 to 7 days before any planned surgery to allow platelet function to recover.
Who Should Not Take Brilinta
Brilinta is not safe for everyone. It is contraindicated in people with a history of bleeding in the brain, because the risk of a recurrent brain bleed is too high. It is also contraindicated in people with active bleeding from any source, such as a stomach ulcer, and in those with severe liver disease, since the liver is responsible for processing the drug. Impaired liver function both increases drug exposure and reduces the body’s ability to make clotting proteins, compounding the bleeding risk.
People who have had an allergic reaction to ticagrelor, including swelling of the face or throat, should not take it again.